Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein
- PMID: 7516416
- PMCID: PMC2191569
- DOI: 10.1084/jem.180.1.389
Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein
Abstract
When merozoites of the malaria parasite Plasmodium falciparum are released from infected erythrocytes and invade new red cells, a component of a protein complex derived from the merozoite surface protein 1 (MSP-1) precursor undergoes a single proteolytic cleavage known as secondary processing. This releases the complex from the parasite surface, except for a small membrane-bound fragment consisting of two epidermal growth factor (EGF)-like domains, which is the only part of MSP-1 to be carried into invaded erythrocytes. We report that, a group of monoclonal antibodies specific for epitopes within the EGF-like domains, some interfere with secondary processing whereas others do not. Those that most effectively inhibit processing have previously been shown to prevent invasion. Other antibodies, some of which can block this inhibition, not only do not prevent invasion but are carried into the host cell bound to the merozoite surface. These observations unequivocally demonstrate that the binding of antibody to the COOH-terminal region of MSP-1 on the merozoite surface may not be sufficient to prevent erythrocyte invasion, and show that the interaction of different antibodies with adjacent epitopes within the EGF-like domains of MSP-1 can have distinct biochemical effects on the molecule. Inhibition of MSP-1 processing on merozoites may be a mechanism by which protective antibodies interrupt the asexual cycle of the malaria parasite.
Similar articles
-
Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies.J Exp Med. 1997 Nov 17;186(10):1689-99. doi: 10.1084/jem.186.10.1689. J Exp Med. 1997. PMID: 9362529 Free PMC article.
-
Antibodies against multiple merozoite surface antigens of the human malaria parasite Plasmodium falciparum inhibit parasite maturation and red blood cell invasion.Malar J. 2010 Mar 18;9:77. doi: 10.1186/1475-2875-9-77. Malar J. 2010. PMID: 20298576 Free PMC article.
-
Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum.J Mol Biol. 2001 Apr 13;307(5):1381-94. doi: 10.1006/jmbi.2001.4574. J Mol Biol. 2001. PMID: 11292349
-
Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.Parassitologia. 1999 Sep;41(1-3):409-14. Parassitologia. 1999. PMID: 10697894 Review.
-
A malaria merozoite surface protein (MSP1)-structure, processing and function.Mem Inst Oswaldo Cruz. 1992;87 Suppl 3:37-42. doi: 10.1590/s0074-02761992000700004. Mem Inst Oswaldo Cruz. 1992. PMID: 1343716 Review.
Cited by
-
Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes.PLoS Pathog. 2015 Feb 27;11(2):e1004670. doi: 10.1371/journal.ppat.1004670. eCollection 2015 Feb. PLoS Pathog. 2015. PMID: 25723550 Free PMC article.
-
Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria.Infect Immun. 2003 Apr;71(4):1833-42. doi: 10.1128/IAI.71.4.1833-1842.2003. Infect Immun. 2003. PMID: 12654798 Free PMC article.
-
Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.PLoS One. 2010 Oct 28;5(10):e13727. doi: 10.1371/journal.pone.0013727. PLoS One. 2010. PMID: 21060850 Free PMC article.
-
Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial.NPJ Vaccines. 2020 Jan 31;5(1):10. doi: 10.1038/s41541-020-0160-2. eCollection 2020. NPJ Vaccines. 2020. PMID: 32025341 Free PMC article.
-
Functional Characterization of Plasmodium falciparum Surface-Related Antigen as a Potential Blood-Stage Vaccine Target.J Infect Dis. 2018 Jul 24;218(5):778-790. doi: 10.1093/infdis/jiy222. J Infect Dis. 2018. PMID: 29912472 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials